Eos acts as a bridge between everyday investors and complex science and technology companies, combining an angel syndicate, an annual EIS fund, and a growth-stage vehicle so it can back Scottish spinouts from their first check through later rounds, backed by a team that includes scientists, former tech-transfer insiders, and figures like world-record cyclist Mark Beaumont who help attract global co-investors. Its portfolio focuses on hard-to-commercialize science and engineering, such as cancer diagnostics, soft robotics, and gene-silencing therapeutics, supported by partnerships like one with US-based Kineticos aimed at funneling over £10 million into Scottish oncology ventures, and by backing from British Business Investments, which committed £10 million to invest alongside Eos's syndicate and fund.